Alzinova operates as a biotechnology company engaged in drug discovery research for Alzheimer’s disease.
Alzinova has raised $1.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Alzinova's investors include Maida Vale Capital, EISMEA.
Alzinova is headquartered in Gothenburg, Sweden.
Alzinova operates as a biotechnology company engaged in drug discovery research for Alzheimer’s disease.
Alzinova is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alzinova — Funding & Investors." VCBacked, June 8, 2026, https://www.vcbacked.co/company/alzinova. Accessed August 15, 2026.
VCBacked. (2026). Alzinova — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/alzinova
{{cite web |title=Alzinova — Funding & Investors |url=https://www.vcbacked.co/company/alzinova |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated